BUFFALO, N.Y., Feb. 25 /PRNewswire/ -- Kinex Pharmaceuticals has appointed Rudolf Kwan, MD, as Chief Medical Officer.
In the clinical operations position, Dr. Kwan successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific.
Earlier at Schering Plough, Dr. Kwan held various clinical operation positions with increasing responsibility. He held similar positions at Chiron Corporation and at Smith Kline Beecham.
“Kinex Pharmaceuticals is extremely pleased to announce that Dr. Rudolf Kwan is joining us as Chief Medical Officer. He brings with him a distinguished career of achievements in clinical operations in the pharmaceutical industry,” said Dr. Allen Barnett, CEO of Kinex.
About Kinex Pharmaceuticals
Kinex is a Buffalo, NY based, privately held biopharmaceutical company committed to the discovery and development of novel therapeutics. The Company’s platform technologies, Mimetica(TM) and Opal(TM), provide unique insight into the design and synthesis of target-based small molecule inhibitors that selectively act on proteins that play key roles in cancer and immuno-inflammatory diseases.
For more information, visit www.kinexpharma.com.
CONTACT: Lyn Dyster of Kinex Pharmaceuticals, +1-716-881-8984
Web site: http://www.kinexpharma.com/
